It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile


call (888) 352-RUSH for help arranging an appointment

Jacob Rotmensch, MD

Patient Feedback
  • Gynecologic Oncology
  • Obstetrics and Gynecology
Board Certification:
  • Gynecologic Oncology
  • Obstetrics & Gynecology
Faculty Rank: Professor
Medical or Graduate Education: Meharry Medical College School of Medicine
Residency: Johns Hopkins Hospital - Obstetrics and Gynecology
Fellowship: Johns Hopkins Hospital - Gynecologic Oncology
Clinical Expertise:
  • Cervical cancer
  • Endometrial cancer
  • Gynecologic cancer
  • Hysterectomy
  • Laparoscopy
  • Ovarian cancer
  • Polycystic ovary syndrome (PCOS)
  • Uterine cancer
  • Vaginal cancer
  • Vulvar cancer
Research Interests:
  • Novel radioisotopes for the treatment of ovarian carcinoma
Google Map
Google Map
Google Map
Google Map
Google Map
Google Map
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

  1. A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: An NRG Oncology/Gynecologic Oncology Group Study.
    Duska LR, Blessing JA, Rotmensch J, Mannel RS, Hanjani P, Rose PG, Dizon DS
    Gynecol. Oncol.
    2014 Oct
  2. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study.
    Campos SM, Brady WE, Moxley KM, O'Cearbhaill RE, Lee PS, DiSilvestro PA, Rotmensch J, Rose PG, Thaker PH, O'Malley DM, Hanjani P, Zuna RE, Hensley ML
    Gynecol. Oncol.
    2014 Jun
  3. Immunohistochemical characterization of squamous differentiation and morular metaplasia in uterine endometrioid adenocarcinoma.
    Blanco LZ Jr, Heagley DE, Lee JC, Gown AM, Gattuso P, Rotmensch J, Guirguis A, Dewdney S, Bitterman P.
    Int J Gynecol Pathol. 2013
    2013 May
    32(3):283-92. doi: 10.1097/PGP.0b013e31826129e1.
  4. Use of cervical mucus to screen for gynecological malignancies: a pilot study.
    Lamzabi I, Buckingham L, Gebrekiristos M, Jain R, Gattuso P, Reddy V, Guirguis A, Dewdney S, Rotmensch J, Bitterman P.
    Mod Pathol. 2013
    2013 Jun 14. doi: 10.1038/modpathol.2013.92. [Epub ahead of print]
  5. Structural and mechanical profiles of native collagen fibers in vaginal wall connective tissues.
    Sridharan I, Ma Y, Kim T, Kobak W, Rotmensch J, Wang R.
    Biomaterials. 2012
    2012 Feb
    33(5):1520-7. doi: 10.1016/j.biomaterials.2011.11.005. Epub 2011 Nov 21.
  6. Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogenesis in laying hen model of spontaneous ovarian cancer.
    Yellapa A, Bahr JM, Bitterman P, Abramowicz JS, Edassery SL, Penumatsa K, Basu S, Rotmensch J, Barua A.
    Int J Gynecol Cancer. 2012
    2012 Feb
    22(2):199-207. doi: 10.1097/IGC.0b013e318236a27b.
  7. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study.
    Alvarez EA, Brady WE, Walker J, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn D, Harrison CR, Moore KN, Aghajanian C.
    Gynecol Oncol. 2012
    2012 Dec 20. doi:pii: S0090-8258(12)00970-5. 10.1016/j.ygyno.2012.12.022. [Epub ahead of print]
  8. Expression of death receptor 6 by ovarian tumors in laying hens, a preclinical model of spontaneous ovarian cancer.
    Barua A, Yellapa A, Bahr JM, Abramowicz JS, Edassery SL, Basu S, Rotmensch J, Bitterman P.
    Transl Oncol. 2012
    2012 Aug
    5(4):260-8. Epub 2012 Aug 1.
  9. Expression of Leukocyte Inhibitory Immunoglobulin-like Transcript 3 Receptors by Ovarian Tumors in Laying Hen Model of Spontaneous Ovarian Cancer.
    Khan MF, Bahr JM, Yellapa A, Bitterman P, Abramowicz JS, Edassery SL, Basu S, Rotmensch J, Barua A.
    Transl Oncol. 2012
    2012 Apr
    5(2):85-91. Epub 2012 Apr 1.
  10. Helical tomotherapy delivery of an IMRT boost in lieu of interstitial brachytherapy in the setting of gynecologic malignancy: feasibility and dosimetric comparison.
    Gielda BT, Shah AP, Marsh JC, Smart JP, Bernard D, Rotmensch J, Griem KL.
    Med Dosim. 2011
    2011 Summer
    36(2):206-12. doi: 10.1016/j.meddos.2010.03.005. Epub 2010 May 26.
  11. Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells.
    Li LC, Jayaram S, Ganesh L, Qian L, Rotmensch J, Maker AV, Prabhakar BS.
    Am J Obstet Gynecol. 2011
    2011 Oct
    205(4):362.e12-25. doi: 10.1016/j.ajog.2011.05.035. Epub 2011 May 27.
  12. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group.
    Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch J, De Geest K, Bonebrake AJ, Walker JL.
    Gynecol Oncol. 2011
    2011 Mar
    120(3):459-63. doi: 10.1016/j.ygyno.2010.11.012. Epub 2010 Dec 7.
  13. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
    Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK.
    J Clin Oncol. 2011
    2011 Jun 1
    29(16):2259-65. doi: 10.1200/JCO.2010.32.6397. Epub 2011 May 2.
  14. Optimal surgical debulking in uterine papillary serous carcinoma affects survival.
    Patsavas K, Woessner J, Gielda B, Rotmensch J, Yordan E, Bitterman P, Guirguis A.
    Gynecol Oncol. 2011
    2011 Jun 1
    121(3):581-5. doi: 10.1016/j.ygyno.2010.11.048. Epub 2011 Mar 25.
  15. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors.
    Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, Kamat A, Sood AK, Levenson V.
    Gynecol Oncol. 2011
    2011 Jan
    120(1):113-20. doi: 10.1016/j.ygyno.2010.09.019. Epub 2010 Nov 6.
  16. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.
    Tait DL, Blessing JA, Hoffman JS, Moore KN, Spirtos NM, Lachance JA, Rotmensch J, Miller DS.
    Gynecol Oncol. 2011
    2011 Apr
    121(1):118-21. doi: 10.1016/j.ygyno.2010.11.027. Epub 2010 Dec 14.
  17. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
    Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J.
    Int J Gynecol Cancer. 2010
    2010 Oct
  18. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study.
    Rocereto TF, Brady WE, Shahin MS, Hoffman JS, Small L, Rotmensch J, Mannel RS.
    Gynecol Oncol. 2010
    2010 Mar
    116(3):332-4. doi: 10.1016/j.ygyno.2009.10.071. Epub 2009 Nov 17. Erratum in: Gynecol Oncol. 2010 Aug 1;118(2):208.
  19. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study.
    Kornblith AB, Huang HQ, Walker JL, Spirtos NM, Rotmensch J, Cella D.
    J Clin Oncol. 2009
    2009 Nov 10
    27(32):5337-42. doi: 10.1200/JCO.2009.22.3529. Epub 2009 Oct 5. Erratum in: J Clin Oncol. 2010 Jun 1;28(16):2805.
  20. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W; Gynecologic Oncology Group.
    Gynecol Oncol. 2009
    2009 Nov
    115(2):215-20. doi: 10.1016/j.ygyno.2009.07.023. Epub 2009 Aug 26.
  21. Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer.
    Barua A, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, Bradaric MJ, Edassery SL, Rotmensch J, Luborsky JL.
    Int J Gynecol Cancer. 2009
    2009 May
    19(4):531-9. doi: 10.1111/IGC.0b013e3181a41613.
  22. A dosimetric comparison of Xoft Axxent Electronic Brachytherapy and iridium-192 high-dose-rate brachytherapy in the treatment of endometrial cancer.
    Dickler A, Kirk MC, Coon A, Bernard D, Zusag T, Rotmensch J, Wazer DE.
    Brachytherapy. 2008
    2008 Oct-Dec
    7(4):351-4. doi: 10.1016/j.brachy.2008.05.003. Epub 2008 Sep 9.
Patient feedback information is available for physicians employed by Rush University Medical Center who have received 30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Number of Patient Surveys
Friendliness/courtesy of the care provider
Explanations the care provider gave you about your problem or condition
Concern the care provider showed for your questions or worries
Likelihood of your recommending this care provider to others
Care provider's efforts to include you in decisions about your treatment
Information the care provider gave you about medications
Instructions the care provider gave you about follow-up care
Your confidence in this care provider
Degree to which care provider talked with you using words you could understand
Amount of time the care provider spent with you
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.